Trial Profile

A first-in-man clinical trial of once weekly subcutaneous injection formulation of exenatide (FT228) in healthy volunteers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions; First in man

Most Recent Events

03 Jan 2017 This trial was planned by Flamel Technologies. The company has completed cross-border merger and became Avadel Pharmaceuticals plc, according to a Flamel Technologies media release.
24 Dec 2015 New trial record
22 Dec 2015 Interim results published in a Flamel Technologies media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com